Status and trend analysis of prophylactic usage of recombinant factor VIII in Chinese pediatric patients with hemophilia A: ReCare - a retrospective, phase IV, non-interventional study
机构：[1]Department of Hematology and Oncology, Shenzhen Children’s Hospital, Shenzhen, China[2]Hemophilia Treatment Centre, Shandong Blood Centre, Jinan, China[3]Department of Hematology, Peking Union Medical College Hospital, Beijing, China[4]Hematology/Oncology Centre, Beijing Children’s Hospital, Capital Medical University, Beijing, China首都医科大学附属北京儿童医院[5]Department of Hematology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology (HUST), Hankou, Wuhan, China内科系统血液内科华中科技大学同济医学院附属同济医院[6]Department of Hematology, The Children’s Hospital, Zhengjiang University School of Medicine, Hangzhou, China[7]Department of Hematology, Nan fang Hospital, Southern Medical University, Guangzhou, China[8]Thrombosis and Hemostasis Centre, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China[9]Department of Hematology, Chengdu Women & Children’s Central Hospital, Chengdu, China[10]Department of Hematology, Nanjing Drum Tower Hospital, Nanjing University Medical School, Nanjing, China[11]Department of Hematology, Dalian Municipal Central Hospital, Dalian Medical University, Dalian, China[12]Department of Hematology, Northern Jiangsu People’s Hospital, Clinical Medical School of Yangzhou University, Yangzhou, China内科系统血液内科江苏省人民医院[13]Bayer HealthCare Pharmaceuticals Inc., Beijing, China
Background: No study has reported the status and chronological trend of prophylactic recombinant factor VIII (rFVIII) use in Chinese pediatric patients with hemophilia A (HA). Objective: We aimed to analyze the status and trend of rFVIII-containing prophylaxis in Chinese pediatric patients with HA. Methods: ReCARE (Retrospective study in Chinese pediatric hemophilia A patients with rFVIII contained REgular prophylaxis) was a retrospective study conducted in 12 hemophilia treatment centers across China. The trend of prophylaxis was evaluated by determining the mean duration of prophylaxis, mean injection frequency (per week), mean dose of each injection (IU/kg), mean total dose injected/week (IU) and proportion of rFVIII consumption relative to factor VIII (FVIII) consumption over the study period. Results: We analyzed 183 male pediatric patients with HA (mean age, 7.14.23 years), who received intermittent prophylaxis between 1 November 2007 and 31 May 2013. The mean duration of prophylaxis with rFVIII increased from 16.72 weeks in 2008 to 32.77 in 2012. Per injection dose of rFVIII increased significantly from 2008 to 2013 (25.89 to 28.31IU/kg, p<.001). An increase was also reported in the mean total FVIII consumed (699.97173.25IU in 2008 and 891.30 +/- 730.341 in 2013) and mean proportion of rFVIII used (33.33 +/- 57.73% in 2008 to 85.50 +/- 29.077% in 2013). Conclusion: Our data revealed an overall improvement in treatment dosage and duration with an increase in the number of patients receiving prophylaxis. The total proportion of rFVIII also increased gradually indicating the development of economy and safety awareness.
基金：
Bayer Healthcare Co. Ltd.
语种：
外文
被引次数：
WOS：
PubmedID：
中科院(CAS)分区：
出版当年[2016]版：
大类|3 区医学
小类|3 区医学：内科3 区医学：研究与实验
最新[2023]版：
大类|4 区医学
小类|3 区医学：内科4 区医学：研究与实验
JCR分区：
出版当年[2015]版：
Q1MEDICINE, GENERAL & INTERNALQ2MEDICINE, RESEARCH & EXPERIMENTAL
最新[2023]版：
Q1MEDICINE, GENERAL & INTERNALQ3MEDICINE, RESEARCH & EXPERIMENTAL
第一作者机构：[1]Department of Hematology and Oncology, Shenzhen Children’s Hospital, Shenzhen, China
共同第一作者：
通讯作者：
通讯机构：[10]Department of Hematology, Nanjing Drum Tower Hospital, Nanjing University Medical School, Nanjing, China[*1]Department of Hematology, Peking Union Medical College Hospital, No.1 Shuaifuyuan wangfujing, Beijing, China
推荐引用方式(GB/T 7714)：
Li Changgang,Zhang Xinsheng,Zhao Yongqiang,et al.Status and trend analysis of prophylactic usage of recombinant factor VIII in Chinese pediatric patients with hemophilia A: ReCare - a retrospective, phase IV, non-interventional study[J].CURRENT MEDICAL RESEARCH AND OPINION.2017,33(9):1571-1578.doi:10.1080/03007995.2017.1333489.
APA：
Li, Changgang,Zhang, Xinsheng,Zhao, Yongqiang,Wu, Runhui,Hu, Qun...&Hou, Qingsong.(2017).Status and trend analysis of prophylactic usage of recombinant factor VIII in Chinese pediatric patients with hemophilia A: ReCare - a retrospective, phase IV, non-interventional study.CURRENT MEDICAL RESEARCH AND OPINION,33,(9)
MLA：
Li, Changgang,et al."Status and trend analysis of prophylactic usage of recombinant factor VIII in Chinese pediatric patients with hemophilia A: ReCare - a retrospective, phase IV, non-interventional study".CURRENT MEDICAL RESEARCH AND OPINION 33..9(2017):1571-1578
